<DOC>
	<DOCNO>NCT02285751</DOCNO>
	<brief_summary>High `` treatment '' platelet reactivity define poor pharmacodynamic response administration acetylsalicylic acid clopidogrel . acetylsalicylic acid clopidogrel drug commonly use reduce platelet activity prevent cardiovascular event . High `` treatment '' platelet reactivity associate high cardiovascular event rate . Ticagrelor prasugrel , like clopidogrel P2Y12 inhibitor effective treat patient High `` treatment '' platelet reactivity clopidogrel . Critically ill patient unique population alter pharmacokinetic pharmacodynamic property . Gastrointestinal dysmotility associate altered resorption impair microvascular function occur frequently critically ill patient may lead altered resorption orally administer drug . The investigator test minimum 100 patient treat 100mg acetylsalicylic acid per o 100 patient treat 75mg clopidogrel per o calculate prevalence high `` treatment '' platelet reactivity . 30 patient high `` treatment '' platelet reactivity acetylsalicylic acid randomize three new treatment group . In first group patient receive 200mg acetylsalicylic acid per o , second group 100mg acetylsalicylic acid intravenously third group 81mg chewable acetylsalicylic acid . Each group contain 10 patient . Pharmacokinetics pharmacodynamics reassess evaluate new treatment . 36 patient high `` treatment '' platelet reactivity clopidogrel randomize receive either additional loading dose 600mg clopidogrel ( n=24 ) continue normal treatment control group ( n=12 ) . Pharmacokinetics pharmacodynamics reassess patient , test high `` treatment '' platelet reactivity spite additional loading dose , randomize receive either ticagrelor prasugrel . The investigator expect six patient per group . The twelve patient control group continue normal treatment ( 75mg/day ) end study . Pharmacokinetics pharmacodynamics ticagrelor prasugrel assess . Any patient , test high `` treatment '' platelet reactivity spite receive prasugrel ticagrelor , finally switch opposite drug final high `` treatment '' platelet reactivity test conduct . 16 patient treat 10mg prasugrel per o test HTPR positively test switch 2x90mg ticagrelor per o per day . Platelet reactivity reassess test whether switch medication benefit patient .</brief_summary>
	<brief_title>High `` Treatment '' Platelet Reactivity Intensive Care Unit</brief_title>
	<detailed_description />
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>&gt; 18years age admittance intensive care unit recent surgery active bleeding know coagulation disorder discretion physician terminal illness ( anticipated life expectancy &lt; 3months ; e.g . due cancer ) pregnancy &lt; 20000 platelet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>high treatment platelet reactivity</keyword>
	<keyword>acetylsalicylic acid</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>prasugrel</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>critically ill</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>